Human Oncology & Pathogenesis Program

Our teams of physician-scientists are working to translate molecular insights into new treatments for cancer.

Physician-scientist David Solit focuses on the development of cancer therapies that target pathways responsible for cancer initiation and progression.

Physician-scientist James Fagin focuses on the pathogenesis of thyroid cancer and the role of oncogenic kinases.

Physician-scientist Ping Chi studies genetic and epigenetic mechanisms of transcriptional regulation by oncogenic transcription factors in GIST and other solid tumors.

Physician-scientist Sarat Chandarlapaty studies the regulation of growth factor signaling networks in cancer.

Browse our lab heads

HOPP Year in Review

One of the goals of the Human Oncology and Pathogenesis Program (HOPP) is to achieve progress in various areas of cancer research. In our 2011 Year in Review, learn about our collaborations, innovations, and training that have had an impact on Memorial Sloan Kettering and its patients.

View report »

DNA wrapped around histones
What Is Epigenetics?

Physician-scientist Omar Abdel-Wahab explains epigenetics, a growing field based on the study of genetic changes that are not part of the DNA code, and how it relates to cancer.

DNA wrapped around histones
Prostate Cancer Organoids Provide New Tool for Evaluating Therapies

Researchers have created tiny structures called organoids from patients’ prostate tumors. These organoids will allow the study of tumors in greater detail and enable correlation of genetic mutations with drug response.

Tumor DNA in Bloodstream May Yield New Cancer Insights

Experimental pathologist Jorge Reis-Filho explains how tumor DNA obtained from the blood could lead to noninvasive — yet highly sensitive — ways of detecting and monitoring cancer in the body.

Pictured: Marc Ladanyi
Gene Mutation Linked to Aggressive Form of Sarcoma Affecting Children and Young Adults

A newly discovered gene mutation appears to be the driving force behind a particularly aggressive form of embryonal rhabdomyosarcoma, a rare cancer of the skeletal muscle.

Pictured: Marc Ladanyi
Pictured: Michael Berger
New Tumor Sequencing Test Will Bring Personalized Treatment Options to More Patients

A powerful diagnostic test, MSK-IMPACT™ gives our doctors an unparalleled amount of information about individual people’s cancers to guide their treatment.

Pictured: Michael Berger